$AMGN · Amgen Inc.
Amgen reported third quarter 2026 financial results on November 3, 2026. Total revenues increased 8% to $10.4 billion compared with the prior-year quarter, driven by 8% growth in product sales. GAAP earnings per share rose 19% to $7.08, while non-GAAP earnings per share increased 14% to $6.45. GAAP operating income grew from $2.5 billion to $3.7 billion, and non-GAAP operating income increased from $4.3 billion to $4.7 billion.
Product performance was mixed. Repatha sales grew 37% to $1,085 million, EVENITY rose 39% to $751 million, TEZSPIRE increased 43% to $538 million, and UPLIZNA climbed 191% to $451 million. In contrast, Prolia sales fell 45% to $632 million and XGEVA declined 47% to $288 million as multiple biosimilars launched globally. Otezla decreased 18% to $481 million. The company generated $3.7 billion of free cash flow in the quarter, down from $4.2 billion a year earlier, primarily due to changes in working capital.